In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors

J Chemother. 1993 Jun;5(3):147-50. doi: 10.1080/1120009x.1993.11739223.

Abstract

Cefodizime (formerly HR221) was tested either for in vitro microbiological activity or for its stability to beta-lactamases in the presence of two beta-lactamase inhibitors (clavulanic acid, tazobactam). Cefodizime was a poor substrate of class C enzymes but hyperproducer strains were generally resistant with or without a beta-lactamase inhibitor used in combination. On the contrary, class A enzymes were able to hydrolyze cefodizime. However, strains expressing class A beta-lactamase were susceptible to cefodizime in combination with clavulanic acid.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Cefotaxime / analogs & derivatives*
  • Cefotaxime / antagonists & inhibitors
  • Cefotaxime / pharmacology
  • Clavulanic Acid
  • Clavulanic Acids / pharmacology*
  • Drug Combinations
  • Drug Interactions
  • Drug Stability
  • Humans
  • Microbial Sensitivity Tests
  • Penicillanic Acid / pharmacology*
  • Tazobactam
  • beta-Lactamase Inhibitors*

Substances

  • Anti-Bacterial Agents
  • Clavulanic Acids
  • Drug Combinations
  • beta-Lactamase Inhibitors
  • Clavulanic Acid
  • Penicillanic Acid
  • Cefotaxime
  • Tazobactam
  • cefodizime